# Thymulin: The Zinc-Locked Immune Switch > Thymulin: Research Overview — municipalpeptides — A cited literature summary of thymulin, the zinc-dependent thymic nonapeptide hormone. Covers mechanism, zinc dependency, gene-therapy findings, and safety cautions from the published research. **01 / IMMUNE & THYMIC RESEARCH** A nine-amino-acid thymic hormone that only works bound to zinc — and one of the oldest measured signatures of zinc status in the human immune system. ## The short version Thymulin is a small hormone made by the thymus — the gland behind the breastbone that trains T cells early in life. The hormone only becomes biologically active once it locks onto a zinc ion; the same amino acid chain without zinc does essentially nothing [7]. Once activated, thymulin helps direct how T cells mature and calms an overactive inflammatory signal called NF-kB. Researchers have used this zinc dependency as a tool: because thymulin activity rises and falls with the body's zinc status, measuring it in blood has served as an indicator of zinc-related immune function, including in people [5][6]. Separately, animal studies have tested whether restoring thymulin signaling — through gene therapy delivering the thymulin gene rather than the peptide itself — can reverse existing inflammatory disease, with one 2020 study reversing established asthma pathology in mice [1]. This page describes what these studies found, in the species and models where they found it. It does not describe a human dose, and thymulin is not an approved medicine. ## What it is Thymulin (also called serum thymic factor, or FTS) is a linear nonapeptide with the sequence pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, molecular formula C33H54N12O15 [5]. It is produced exclusively by thymic epithelial cells [4], and its biological activity is strictly conditional: the peptide must bind one zinc(II) ion per molecule, in a defined 1:1 ratio, before it does anything. Researchers established this by stripping zinc from the peptide with a chelating agent, which abolished its activity in a standard immune-cell assay, then restoring activity by adding zinc salts back — the paper that did this coined the name "thymulin" for the zinc-bound, active form, distinguishing it from the inactive zinc-free peptide [7]. Nuclear magnetic resonance work later confirmed the zinc-bound peptide adopts a specific three-dimensional shape that the unbound chain does not [5]. ## How it works Once zinc-bound, thymulin acts on T lymphocytes, steering their differentiation and the balance between T-cell subsets. It also reaches beyond the immune system: thymulin functions as a hypophysiotropic peptide, meaning it signals to the pituitary gland — for example, influencing ACTH release — making it part of a two-way communication loop researchers call the thymus-neuroendocrine axis [2][4]. Mechanistically, much of thymulin's anti-inflammatory effect traces to the NF-kB pathway, one of the cell's central switches for turning inflammatory genes on. In a mouse model of LPS-induced inflammation, daily thymulin dosing for two weeks before the inflammatory trigger reduced pro-inflammatory cytokines, dampened stress-protein induction (HSP72/HSP90alpha), and measurably suppressed NF-kB and a related stress pathway (SAPK/JNK), while also lowering expression of TLR4, one of the receptors that first detects bacterial signals and triggers inflammation [3]. Separate work documents anti-inflammatory and analgesic activity when thymulin signaling reaches the central nervous system [4]. ## What the research shows The most striking single result on this desk is a 2020 gene-therapy study: researchers gave mice a single intratracheal (inhaled) dose of nanoparticles carrying a thymulin-expressing plasmid, but only after fully establishing an allergic-asthma model — meaning the disease was already present, not merely being prevented. At 20 days, the treatment had normalized every major lung pathology researchers measured: chronic inflammation, pulmonary fibrosis, and mechanical lung dysfunction, through combined anti-inflammatory and antifibrotic action [1]. A related gene-therapy strategy — a synthetic thymulin analog called metFTS delivered by regulatable adenovectors — restored circulating thymulin and prevented hormonal and reproductive abnormalities in congenitally athymic ("nude") mice, a model researchers use to study neuroendocrine aging [2]. The zinc-dependency story has direct human data behind it. In adults with mild zinc deficiency — including six people with sickle-cell anemia and six without — serum thymulin activity was reduced despite normal blood zinc levels, and was restored by zinc supplementation given either directly to the blood sample or to the person, alongside reversible shifts in T-cell subsets and interleukin-2 activity [6]. That finding, from 1988, remains one of the field's clearest human demonstrations that thymulin activity tracks zinc status specifically, not just general nutrition. ## Reported effects, cautions & safety Community-reported, real-world accounts of thymulin's effects are not well documented in the literature this corpus draws on — unlike many research peptides, thymulin has little presence in consumer research-use forums, and this site does not manufacture anecdotal reports where none exist in the sourced record. What the literature does establish, plainly, are several cautions. Thymulin is not approved by the FDA for any human use and is handled strictly as a research peptide for laboratory use; most of the supporting evidence remains preclinical, drawn from cell and animal models rather than modern clinical trials. Where human studies do exist, several used a synthetic analog (nonathymulin) rather than native thymulin, which limits how directly those results generalize. Consumer sources online frequently — and incorrectly — conflate thymulin with two chemically and pharmacologically distinct compounds, thymosin alpha-1 and thymalin (a bovine thymic extract); the three are not interchangeable. Some specific consumer-facing claims, including exact regrowth percentages from a small topical zinc-thymulin pilot study, come from single-author, low-tier sources that were not independently corroborated in this corpus and should be treated as preliminary. Because thymulin's activity is inseparable from zinc status, isolating a "thymulin effect" from a "zinc effect" is a persistent interpretive difficulty across the literature. Human pharmacokinetics, including half-life, and any standardized human dosing are not well characterized in the published record. ## Where it fits in Immune & Thymic research On this desk, thymulin is the systemic, hormone-linked half of the immunomodulation story — a peptide whose zinc dependency ties it into whole-body nutritional status as much as into any single disease model, and whose gene-therapy studies test reversing established disease rather than merely preventing it [1][2]. [KPV](/kpv) takes the opposite approach: a locally delivered, gut-targeted peptide with no systemic hormone axis of its own, tested almost entirely in colitis models [8][9][10]. Read them side by side on the [comparison page](/compare) to see how two different immunomodulatory strategies — one systemic, one local — converge on the same inflammatory switch. ![Thymulin research illustration — abstract thymic and immune-signaling motifs](/images/thymulin.webp) --- A data-forward literature survey of thymic and anti-inflammatory peptide research — every figure traced to its source, nothing sold, no dose advised.